title: [The French project ETOILE: review of clinical data for light ion hadrontherapy].
abstract: The Lawrence Berkeley Laboratory was the pioneer in light ions hadrontherapy with almost 2500 patients treated between 1957 and 1993 with Helium and Neon. The NIRS (National Institute For Radiological Science, Chiba, Japan) was the first dedicated medical centre for cancer with more than 1200 patients exclusively treated with carbon ion from 1994. A three-year 70 to 100% local control was reported for radio-resistant cancers, supporting the use of high LET particles. Hypo-fractionation was particularly explored for lung cancers and hepatocarcinoma (4 sessions only). Dose escalation studies demonstrated a tumour dose-effect and permitted to precise dose constraints for healthy tissues especially for the rectum. More than 140 patients were treated with carbon ion exclusively or associated with photons since 1997 in the GSI laboratory Gesellschaft Für Schwerionenforschung, Darmstadt, Germany). A very high local control was also obtained for radioresistant cancer of the base of the skull. Preliminary clinical data seem to confirm the expected therapeutic gain with light ions, due to their ballistic and radio-biological properties, and justify the European projects for the construction of dedicated medical facilities for cancers. The French "Etoile" project will be integrated in the European hadrontherapy network "Enlight", with the objectives to coordinate technologic, medical and economic features.
authors.affiliation: Centre Léon Bérard, 28, rue Laënnec, 69373 cedex 08, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Pommier
authors.forename: J
authors.initials: J
authors.lastname: Balosso
authors.forename: M
authors.initials: M
authors.lastname: Bolla
authors.forename: J P
authors.initials: JP
authors.lastname: Gérard
mesh_terms: D002244:Carbon / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D005602:France; D006371:Helium / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000532:radiotherapy*; D008175:Lung Neoplasms / Q000532:radiotherapy*; D009356:Neon / Q000627:therapeutic use*; D011878:Radiotherapy / Q000379:methods*; D012189:Retrospective Studies; D019292:Skull Base Neoplasms / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D006371:Helium; D009356:Neon; D002244:Carbon